Catalyz bags national award for Best Start up Biotechnology/Pharma Company
Catalyz Scientific Technologies incubated at Technopark Trivandrum TBI won national award for the best start up company in Biotech/Pharma sector for the year 2009.
Tweet
Catalyz bags national award for Best Start up Biotechnology
-- Catalyz Scientific Technologies incubated at Technopark Trivandrum TBI won national award for the best start up company in Biotech/Pharma sector for the year 2009.
Dr. Biju Jacob , Founder and CEO of Catalyz along with Mr. Mervin Alexander CEO of Techopark and Mr. KCC Nair , CFO Technopark received the award from Hon'ble Minister for Science and Technology , Shri Pritviraj Chavan at 4th International Conference on Business Incubation, Habitat Centre ,Delhi .
Dr. T.Ramasami, Secretary, DST, Dr Samir Bramhachari, Secretary DSIR & Director General CSIR, RMP Jawahar, president ISBA, Rajendra Jagdale, secretary general, ISBA, Arindam Dutta, Vice President, ISBA, and Prof Arun Nigavekar, former chairman, UGC, were also present on the occasstion.
KC Chandrashekahr Nair, CFO and Program Head Technopark TBI says "This is the first time a biotechnology company incubated at technopark trivandrum receiving national award for innovation and entrepreneurship, adding one more feather to TBIs cap".
Catalyz is developing effective yet affordable diagnostic systems for infectious and chronic diseases. Catalyz Chief Dr. Biju Jacob claims that their tests needs no technical knowledge or any device to interpret the result, hence making it easy for a laymen in confirming or ruling out certain diseases.
He added "India being a tropical country is prone to several infections and outbreaks of viral diseases. This calls for an increasing need for speedy and specific diagnosis in confirmation of diseases to control potential epidemics . Our diagnostic systems will address these healthcare issues"
Catalyz has been instrumental in launching first Stem Cell Therapy initiative across Kerala State last year. The team has been successful in establishing a pan India network of Stem Cell Therapy units .
Notes to Editor
Catalyz is a new generation Healthcare Innovations Company focused on point of care diagnostics and stem cell therapeutics. We are developing proprietary diagnostics and prognostics platforms for different infectious and chronic diseases. Our tests need no technical knowledge or any device to interpret the result, hence making it easy for laymen in confirming or ruling out certain diseases. India being a tropical country is prone to several infections and outbreaks of viral diseases. This calls for an increasing need for speedy and specific diagnosis in confirmation of diseases to control potential epidemics. Our diagnostic systems will address these healthcare issues.
Catalyz has partnered with several groups around the world, who are doing pioneering work in the area of adult stem cell research and therapy and together we are developing adult stem cell-based therapeutic protocols for a number of incurable diseases. Currently, we offer adult stem cell therapy for several diseases including peripheral artery disease, chronic liver disease, renal failure, diabetic foot ulcers, spinal cord injury, osteoarthritis and muscular dystrophy.
Products:
We are launching an array of affordable point-of-care diagnostic systems that will provide real-time, lab quality results for common blood tests for infectious and chronic diseases. No longer will doctors need to prescribe treatment without test results, and no longer will patients need to return to their doctors' office or lab multiple times. The result is better patient care and better practice economics for the global healthcare market.
Services:
rapid diagnostics partner - Our team of scientists has experience in developing a range of formats of lateral flow tests for a wide variety of applications. We are familiar with semi-quantitative and quantitative assays, multiplex assays, flow through and multi strip technology, using nano-molecules.
stem stem cell biology partner - life sciences organizations, from large pharmaceutical to virtual biotech companies, can benefit from our extensive expertise in stem cell biology, cell-based assays, and cellular therapy.
